Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.
Schistosome and malaria exposure and urban–rural differences in vaccine responses in Uganda: a causal mediation analysis using data from three linked randomised controlled trials
Natukunda A. et al, (2024), The Lancet Global Health, 12, e1860 - e1870
Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial.
Wajja A. et al, (2024), The Lancet. Infectious diseases, 24, 285 - 296
Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control
Wajja A. et al, (2024), The Lancet Infectious Diseases, 24, e78 - e79
BCG-induced non-specific effects on heterologous infectious disease in Ugandan neonates: an investigator-blind randomised controlled trial
Prentice S. et al, (2021), The Lancet Infectious Diseases, 21, 993 - 1003
A genome‐wide association and replication study of blood pressure in Ugandan early adolescents
Lule SA. et al, (2019), Molecular Genetics & Genomic Medicine, 7
Effect of Schistosoma mansoni infection and its treatment on antibody responses to measles catch-up immunisation in pre-school children: A randomised trial
Tweyongyere R. et al, (2019), PLOS Neglected Tropical Diseases, 13, e0007157 - e0007157
Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A
Wajja A. et al, (2018), Wellcome Open Research, 3, 121 - 121
Understanding asthma phenotypes: the World Asthma Phenotypes (WASP) international collaboration
Pembrey L. et al, (2018), ERJ Open Research, 4, 00013 - 2018
The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial
Wajja A. et al, (2017), PLOS Neglected Tropical Diseases, 11, e0005440 - e0005440